健康体检人群中磁共振弹性成像评估显著肝纤维化的患病率
该研究在韩国健康体检队列(2170人)中使用磁共振弹性成像(MRE)调查肝纤维化患病率,发现整体F2和F3患病率分别为5.1%和1.3%(性别年龄标化后3.8%和1.3%),非酒精性脂肪性肝病(NAFLD)患者中显著和进展性纤维化患病率为8.0%和1.5%,合并糖尿病的NAFLD患者F3患病率更高。
要点
- 健康体检人群中MRE定义的显著肝纤维化(≥F2)患病率为5.1%,进展性纤维化(≥F3)为1.3%。
- NAFLD患者中显著和进展性纤维化患病率分别为8.0%和1.5%。
- NAFLD合并糖尿病者F3患病率是单纯NAFLD者的5倍。
核心结论
- 韩国健康体检人群中显著和进展性肝纤维化的患病率分别为5.1%和1.3%(性别年龄标化后3.8%和1.3%)。
- 糖尿病合并NAFLD者进展性肝纤维化患病率是未合并糖尿病者的5倍。
研究设计与样本
- 研究纳入2015年1月至2018年5月在某健康体检门诊的2170名参与者,均接受磁共振化学位移技术和磁共振弹性成像(MRE)检查。
- 主要目标为估计肝纤维化患病率,并基于韩国统计信息服务(KOSIS)2015-2018年数据进行性别和年龄标化。
主要发现
- 整体队列中F2(≥3.0 kPa)和F3(≥3.6 kPa)患病率分别为5.1%和1.3%(性别年龄标化后3.8%和1.3%)。
- 平均风险人群(排除酒精使用和病毒性肝炎)中NAFLD(脂肪分数>5%)患病率为27.7%,NAFLD参与者中显著和进展性纤维化患病率分别为8.0%和1.5%。
- 糖尿病患者中≥F2和≥F3患病率分别为12.5%和4.3%;NAFLD合并糖尿病患者中≥F2和≥F3患病率分别为24.1%和6.0%。
- 多变量分析显示仅年龄、胰岛素、糖尿病和磁共振脂肪肝与显著纤维化独立相关。
关键数值与推荐
- MRE定义显著纤维化为≥3.0 kPa(F2),进展性纤维化为≥3.6 kPa(F3)。
- NAFLD定义为磁共振脂肪分数>5%。
临床怎么用
- 在健康体检人群中可考虑使用MRE筛查显著肝纤维化,尤其对NAFLD合并糖尿病者应加强评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Significant hepatic fibrosis is associated with higher mortality. However, data on the estimated prevalence of liver fibrosis in the general population are scarce. AIM: To use magnetic resonance elastography (MRE) to investigate the prevalence of hepatic fibrosis in a Korean health check-up clinic cohort. METHODS: We enrolled 2170 participants at our health check-up clinic between January 2015 and May 2018, all of whom had MR with chemical shift technique and MRE. The primary objective was to estimate the prevalence of liver fibrosis. For generalisation, sex- and age-standardised prevalence was calculated based on the Korean Statistical Information Service (KOSIS) during the period 2015-2018. RESULTS: The prevalence of F2 (≥3.0 kPa) and F3 (≥3.6 kPa) in the overall cohort was 5.1% and 1.3% respectively (sex- and age-adjusted prevalence of 3.8% and 1.3%). Non-alcoholic fatty liver disease (NAFLD) prevalence (>5% fat fraction) was 27.7% in the average risk population (after excluding alcohol use and viral hepatitis), and the prevalence of significant and advanced fibrosis in NAFLD participants was 8.0% and 1.5% respectively. In participants with diabetes, 12.5% had ≥F2 and 4.3% ≥F3. In participants with NAFLD plus diabetes, 24.1% had ≥F2 and 6.0% ≥F3. On multivariate analysis, only age, insulin, diabetes and fatty liver on MR were independently associated with significant fibrosis. CONCLUSIONS: In a Korean health check-up clinic setting, the prevalence of significant and advanced liver fibrosis was 5.1% and 1.3% (sex- and age-adjusted prevalence of 3.8% and 1.3%). The prevalence of advanced liver fibrosis was five times higher for diabetic participants with NAFLD.
引用
- Kang KA, Jun DW, Kim MS, et al. Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. Aliment Pharmacol Ther. 2020. PMID: 31943268. doi:10.1111/apt.15626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。